Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Date of authorisation: 25/08/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 4, Status: Authorised

PMS Product user interface (PUI) Training: Product data submission & bulk edit made easy, Online, European Medicines Agency, Amsterdam, the Netherlands, from 6 October 2025, 10:00 (CEST) to 6 October 2025, 12:00 (CEST)

Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Date of refusal: 02/05/2025, Status: Refused

European Medicine Agency (EMA) and European Association for the Study of Diabetes (EASD) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 September 2025, 10:30 (CEST) to 26 September 2025, 12:00 (CEST)

European Medicines Agency (EMA) and European Association for the Study of Diabetes (EASD) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 September 2025, 10:30 (CEST) to 26 September 2025, 12:00 (CEST)

Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Date of authorisation: 30/06/2025, Revision: 1, Status: Authorised

Referral: Tecovirimat SIGA, tecovirimat Article 20 procedures Under evaluation, 14/11/2025

European Medicines Agency (EMA) and European Association of Urology (EAU) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 2 October 2025, 16:30 (CEST) to 2 October 2025, 17:30 (CEST)

Human medicines European public assessment report (EPAR): Enflonsia, clesrovimab, Status: Opinion